



Date: 30-05-2024

**To,
Corporate Relationship Department,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai-400001.**

Dear Sir(s),

**Sub: Outcome of Board Meeting -Disclosure under Reg.30 of SEBI (LODR) Regulations, 2015
Scrip Code: 524636**

Pursuant to Regulations 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") read with Schedule III to the said Regulations, this is to inform you that the Board of Directors of the Company, at their meeting held on Thursday, 30th May, 2024, inter alia, transacted the following items of business:

1. Considered and approved the Audited Financial Results for the fourth quarter and Financial Year Ended 31st March, 2024. The said Audited Financial Results were reviewed by the Audit Committee and thereafter approved by the Board of Directors.
2. Appointment of M/s. S Siva Parvathi & Associates, Chartered Accountants, (Firm Registration No.020872S), as the Internal Auditors of the Company for the financial year 2024-25.

Pursuant to Regulation 33 and other applicable regulations, if any, of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the Listing Regulations), we are enclosing herewith:

- a. Audited Financial Results for the fourth quarter and Financial Year Ended 31st March, 2024.
- b. Statement of Assets and Liabilities as at March 31, 2024 and Statement of Cash Flows for the Financial Year Ended 31st March, 2024.
- c. Declaration pursuant to Regulation 33(3) (d) of the SEBI (LODR) Regulations, 2015, regarding unmodified opinion of the Statutory Auditors on the Annual Financial Results for the Financial Year ended on 31st March, 2024.
- d. Auditors reports on the Audited Financial Results for the Financial Year ended on 31st March, 2024.

OXYGENTA PHARMACEUTICAL LIMITED (Formerly known as S.S ORGANICS LIMITED)
(An ISO 9001:2015, ISO 14001 : 2015 and OH&S ISO 45001:2018 Certified Company)

REGD. OFF & FACTORY: Sy. No. 252/1, Aroor (V), Sadasivapet (M), Sangareddy (Dist) – 502 291, Telangana, INDIA.

Tel: (08455) 250080, Fax: 08455-250090

Corp. Office: Plot No.43, Sy. No. 55 to 58, The Park View, 1st Floor, Lumbini Avenue, Gachibowli, Hyderabad – 500 032.

E-Mail id: cs@oxygentapharma.com, info@oxygentapharma.com. Website: www.oxygentapharma.com

CIN: L24110TG1990PLC012038



The Board Meeting of the Company commenced at 03.00 PM and concluded at 10.00 P.M

This is for your information and records.

Regards,

For Oxygenta Pharmaceutical Limited

Name: Sai Sudhakar Vankineni

Designation: Managing Director

DIN.: 00733001

OXYGENTA PHARMACEUTICAL LIMITED (Formerly known as S.S ORGANICS LIMITED)

(An ISO 9001:2015, ISO 14001 : 2015 and OH&S ISO 45001:2018 Certified Company)

REGD. OFF & FACTORY: Sy. No. 252/1, Aroor (V), Sadasivapet (M), Sangareddy (Dist) – 502 291, Telangana, INDIA.

Tel: (08455) 250080, Fax: 08455-250090

Corp. Office: Plot No.43, Sy. No. 55 to 58, The Park View, 1st Floor, Lumbini Avenue, Gachibowli, Hyderabad – 500 032.

E-Mail id: cs@oxygentapharma.com, info@oxygentapharma.com. Website: www.oxygentapharma.com

CIN: L24110TG1990PLC012038

OXYGENTA PHARMACEUTICAL LIMITED

Regd Office Survey No. 252/1, Aroor Village, Sadasivapet Mandal, Sangareddy Dist, Telangana State

Website www.ssgorganics.co.in, Email Ids: ind@oxygentapharma.com, cs@oxygentapharma.com, Phone Number: 040- 23355938

STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 ST MARCH 2024

(Rupees in Lakhs except for EPS)

S. No	Particulars	Quarter Ended	Quarter Ended	Quarter Ended	Year ended	Year ended
		31-March-2024	31-December-2023	31-March-2023	31-Mar-2024	31-Mar-2023
		(Audited)	(Un-Audited)	(Audited)	(Audited)	(Audited)
1	Income					
	(a) Revenue from Operations	1,055.24	914.99	818.58	3,964.21	3,098.75
	(b) Other Income	1.28	2.84	0.10	4.24	1.78
	Total income	1,056.52	917.83	818.68	3,968.45	3,100.52
2	Expenses					
	(a) Cost of materials consumed	904.17	624.90	734.77	3,505.52	2,812.61
	(b) Purchase of stock-in-trade	-	-	-	-	-
	(c) Changes in inventories of finished goods, work- in-progress and stock-in-trade	(211.74)	179.82	(77.76)	(152.68)	(463.48)
	(d) Direct Manufacturing Expenses	(147.16)	298.05	316.59	743.85	1,172.55
	(e) Employee benefit expense	524.69	24.30	41.95	599.37	124.23
	(e) Finance Costs	59.49	36.39	94.06	159.39	148.75
	(f) Depreciation and amortisation expense	63.82	68.85	85.18	266.07	205.18
	(g) Other expenses	146.70	34.99	27.72	237.80	164.53
	Total expenses	1,339.97	1,267.30	1,222.50	5,359.32	4,164.36
3	Profit from operations before other income and exceptional items (1-2)	(283.45)	(349.46)	(403.81)	(1,390.87)	(1,063.83)
4	Other income	-	-	-	-	-
5	Profit from ordinary activities before exceptional items (3+4)	(283.45)	(349.46)	(403.81)	(1,390.87)	(1,063.83)
6	Exceptional (expenses)/income	24.74	(5.14)	(5.43)	3.70	(73.43)
7	Profit / (Loss) from ordinary activities	(258.71)	(354.60)	(409.24)	(1,387.17)	(1,137.27)
8	Tax expense/(credit) - Deferred Tax	(1,060.29)	23.03	19.83	(1,039.24)	19.83
9	Net Profit / (Loss) from ordinary activities	801.58	(377.63)	(429.07)	(347.93)	(1,157.10)
10	Extraordinary items (net of tax expense)	-	-	-	-	-
11	Net Profit / (Loss) for the period (11+ 10)	801.58	(377.63)	(429.08)	(347.93)	(1,157.10)
12	Other Comprehensive Income	7.11	-	-	7.11	-
13	Total Comprehensive Income	808.69	(377.63)	(429.08)	(340.82)	(1,157.10)
14	Share of Profit/(loss) of associates	-	-	-	-	-
15	Minority interest	-	-	-	-	-
16	Paid-up equity share capital (face value Rs. 10/-)	3,348.35	3,348.35	1,420.13	3,348.35	1,420.13
17.i	Earnings per share (before extraordinary items) (of Rs.10/- each) (not annualised):					
	(a) Basic	2.55	(1.12)	(3.02)	(1.09)	(8.15)
	(b) Diluted	2.44	(1.07)	(3.02)	(1.04)	(8.15)
17.ii	Earnings per share (after extraordinary items) (of Rs.10/- each) (not annualised):					
	(a) Basic	2.55	(1.12)	(3.02)	(1.09)	(8.15)
	(b) Diluted	2.44	(1.07)	(3.02)	(1.04)	(8.15)


Notes

- In pursuance with Regulation 33 of SEBI (LODR) Regulations, 2015 and Schedule III of Companies Act, 2013, the above Financial Results have been audited by the Statutory Auditors of Company and recommended by Audit Committee and subsequently approved by Board of Directors of Company at their meeting held on Thursday, May 30th, 2024 at its Corporate office, Plot no. 43, Sy no. 55 to 58, The Park View 1st Floor, Lumbini Avenue, Gachibowli, Hyderabad - 500032.
- The financial results of the company have been prepared in accordance with Indian Accounting Standards (Ind AS) notified under the companies (Indian Accounting standards) Rules, 2015 as amended by the companies (Indian Accounting standards) (Amendment) rules, 2016.
- The entire operations of the Company relate to only one segment i.e Manufacturing of Pharmaceutical Products., Hence, segmental reporting as per IND AS-108 is not made.
- The figures of the current quarter ended March 31, 2024 and the quarter ended March 31, 2023 are the balancing figures between the audited figures in respect of the full financial year ended respectively and published unaudited year to date figures upto the third quarter of the respective financial years.
- The results for the quarter ended 31st March 2024 are also available on the website of the stock exchange i.e BSE Limited and on the Company's website i.e www.oxygentapharma.com
- The Share warrants issued are considered for calculation of Diluted EPS during the period.
- The deferred tax has not been calculated on the company's losses, nor on the provisions for gratuity and leave encashment recorded in the books of accounts. Upon calculation, it was observed that these factors are reducing the company's losses for the year.
- The company has received the GST Assessment Order for the financial year 2017-18, indicating a GST liability of INR 6,001,339. The company has accepted liability for INR 1,869,988 and has filed an appeal with the Appellate Authority regarding the disputed balance of INR 4,131,351.
- Previous period/year figures have been regrouped and rearranged wherever necessary to facilitate comparison.

For and on behalf of the Board of Directors
OXYGENTA PHARMACEUTICAL LIMITED

Sai S udhakar

SAI SUDHAKAR VANKINENI
Managing Director
DIN :00733001



Place: Hyderabad
Date: 30th May, 2024

OXYGENTA PHARMACEUTICAL LIMITED
CIN: L24110TG1990PLC012038

Statement of Assets & Liabilities as at 31 March 2024


(Rupees in Lakhs)

	As at	As at
	31 March 2024	31 March 2023
Assets		
Non-current assets		
Property, plant and equipment	2,935.84	2,791.34
Capital work-in-progress	-	-
Intangible assets		
Financial assets		
Investments	4.94	4.94
Loans	41.94	41.97
Trade Receivables	-	39.66
Others Financial assets	52.61	47.93
Deferred tax assets, net	873.30	-
Other Non Current Assets	-	-
Total non-current assets	3,908.62	2,926
Current assets		
Inventories	1,371.65	1,170.51
Financial assets		
Investments	-	-
Trade receivables	736.06	1,015.97
Cash and cash equivalents	0.17	1.75
Other balances with banks	9.91	8.87
Loans	-	-
Others Financial assets	-	-
Other current assets	292.80	303.52
Total current assets	2,410.59	2,500.62
Total assets	6,319.21	5,426.47
Equity and Liabilities		
Equity		
Equity share capital	3,348.35	1,420.13
Other equity	(5,360.59)	(6,040.13)
Total equity	(2,012.24)	(4,620.00)
Liabilities		
Non-current liabilities		
Financial Liabilities		
Borrowings	4,900.17	6,225.26
Lease Liabilities	-	-
Trade payables		
- total outstanding dues of micro enterprises and small enterprises	-	-
- total outstanding dues of creditors other than micro enterprises and small enterprises	-	306.51
Provisions	61.78	58.98
Deferred Tax Liabilities	-	165.94
Other Non current liabilities		
Total Non current liabilities	4,961.95	6,756.69
Current liabilities		
Financial Liabilities		
Borrowings	823.20	574.09
Lease Liabilities	-	-
Trade payables		
-total outstanding dues of micro enterprises and small enterprises	330.78	-
-total outstanding dues of Creditors otherthan micro enterprises and small enterprise	1,957.95	2,377.95
Other financial liabilities	-	-
Provisions	-	52.21
Other current liabilities	257.57	285.54
Income tax liabilities(net)		
Total current liabilities	3,369.51	3,289.79
Total liabilities	8,331.46	10,046.48
Total equity and liabilities	6,319.21	5,426.47



for and on behalf of the Board of Directors of
OXYGENTA PHARMACEUTICAL LIMITED

V Sai Sudhakar

Dr V Sai Sudhakar
Managing Director
DIN : 00733001



Place: Hyderabad
Date: 30th May, 2024

OXYGENTA PHARMACEUTICAL LIMITED CIN: L24110TG1990PLC012038		
Cash Flow Statement for the Year Ended 31st March 2024		
	Rs in Lakhs	
	For the year ended 31 March 2024	For the year ended 31 March 2023
I. Cash flows from operating activities		
Profit before tax	(1,387.17)	(1,137.27)
<i>Adjustments to reconcile profit before tax to net cash flows:</i>		
Depreciation of tangible assets	266.07	205.18
Amortisation of intangible assets	-	-
Finance income (including fair value change in financial instruments)	(1.78)	(0.50)
Dividend income from mutual funds	-	-
Forex (Gain)/Loss	(1.35)	-
Finance costs (including fair value change in financial instruments)	159.39	148.75
Re-measurement losses/Gains on defined benefit plans	8.46	-
Operating profit before working capital changes	(956.38)	(783.84)
<i>Changes in working capital:</i>		
Adjustment for (increase)/decrease in operating assets		
Trade receivables - Non current	39.66	(2.85)
Trade receivables - current	279.92	(858.38)
Inventories	(201.14)	(442.20)
Loans - Non current	0.03	-
Loans - current	-	-
Other financial assets - current	-	-
Other assets - current	10.72	(248.62)
Other assets - non current	(4.68)	(2.41)
Adjustment for (increase)/decrease in operating liabilities		
Trade payables	(395.72)	2,120.67
Other financial liabilities - current	(80.18)	54.28
Short Term Borrowings	-	-
Provisions - Non Current	2.80	-
Cash generated from operations	(1,304.96)	(163.37)
Interest Paid	-	-
Deferred Taxes/ Income taxes paid/charged	-	-
Net cash generated from/(used in) operating activities	(1,304.96)	(163.37)
II. Cash flows from investing activities		
Purchase of property, plant and equipment and intangibles (including capital work in progress) (Investments in)/ redemption of bank deposits (having original maturity of more than three months) - net	(410.57)	(964.50)
Dividend received on mutual funds	-	-
Interest received (finance income)	1.78	0.50
Net cash used in investing activities	(408.78)	(963.99)
III. Cash flows from financing activities		
Proceeds from Share Capital	2,892.33	-
Proceeds from Issue of Share Warrants	56.25	-
Proceeds from/(repayment of) long-term borrowings, net	(1,075.98)	1,271.17
Interest paid	(159.39)	(148.75)
Net cash provided by financing activities	1,713.20	1,122.41
Net increase in cash and cash equivalents (I+II+III)	(0.54)	(4.95)
Cash and cash equivalents at the beginning of the year	10.62	15.57
Cash and cash equivalents at the end of the year (refer note below)	10.08	10.62
Note:		
Cash and cash equivalents comprise:		
Cash on hand	0.00	0.02
Balances with banks:		
- in current accounts & Deposits	10.08	10.60
	10.08	10.62
for and on behalf of the Board of Directors of OXYGENTA PHARMACEUTICAL LIMITED		
 Dr V Sai Sudhakar Managing Director DIN 00733001		
Place: Hyderabad Date: 30th May, 2024		



Date: 30th May 2024

To
Corporate Relations Department
BSE Limited
P.J. Towers, Dalal Street,
Mumbai-400001

Dear Sir,

Sub: Declaration Pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for Unmodified Opinion.

**Ref No. Scrip Code: 524636
DECLARATION FOR UNMODIFIED OPINION**

I, Sai Sudhakar Vankineni, Managing Director of M/s. Oxygenta Pharmaceutical Limited having its Registered office at No.252/1, Aroor village, Sadasivapet Mandal, Medak District, Telangana, India, hereby declare that, M/s. A M Reddy & D R Reddy, Statutory Auditors of the Company, have issued an Audit Report with Unmodified Opinion on Standalone Audited Financial Results for the Quarter and Year Ended 31st March, 2024.

This Declaration is issued in compliance of Regulation 33(3)(d) of the SEBI (LODR) Regulations 2015 as amended.

Thanking You,
Yours Faithfully,

For Oxygenta Pharmaceutical Limited

Sai Sudhakar



Name: Sai Sudhakar Vankineni
Designation: Managing Director
DIN.: 00733001

OXYGENTA PHARMACEUTICAL LIMITED (Formerly known as S.S ORGANICS LIMITED)

(An ISO 9001:2015, ISO 14001 : 2015 and OH&S ISO 45001:2018 Certified Company)

REGD. OFF & FACTORY: Sy. No. 252/1, Aroor (V), Sadasivapet (M), Sangareddy (Dist) – 502 291, Telangana, INDIA.
Tel: (08455) 250080, Fax: 08455-250090

Corp. Office: Plot No.43, Sy. No. 55 to 58, The Park View, 1st Floor, Lumbini Avenue, Gachibowli, Hyderabad – 500 032.

E-Mail id: cs@oxygentapharma.com, info@oxygentapharma.com. Website: www.oxygentapharma.com

CIN: L24110TG1990PLC012038



A.M REDDY & D.R REDDY Chartered Accountants

Independent Auditor's Report on Quarterly Financial Results and Year to Date Financial Results pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015

To the Board of Directors of Oxygenta Pharmaceutical Limited

Report on the Audit of Financial Results

Opinion

We have audited the accompanying annual financial results of Oxygenta Pharmaceutical Limited (hereinafter referred to as 'the Company') for the quarter and year ended March 31, 2024 ('the Statement'), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Statement:

- (i) are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- (ii) give a true and fair view in conformity with the applicable accounting standards prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with Companies (Indian Accounting Standards) Rules, 2015, as amended, and other accounting principles generally accepted in India, of net loss and other financial information of the Company for the year ended March 31, 2024.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics.

We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.

Board of Directors' Responsibilities for the Financial Results

This Statement has been prepared on the basis of the annual financial statements. The Company's Board of Directors are responsible for the preparation and presentation of this Statement that give a true and fair view of the net loss in accordance with the Indian Accounting Standards prescribed under Section 133 of the Act read with Companies (Indian Accounting Standards) Rules, 2015, as amended issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Board of Directors of the Company are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Statement by the Directors of the Company, as aforesaid.

In preparing the Statement, the Board of Directors of the Company are responsible for assessing the ability of the Company to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors of the Company are responsible for overseeing the financial reporting process of the Company.

Auditor's Responsibilities for the Audit of the Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance of the Company of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matters

The Statement includes the results for the quarter ended March 31, 2024 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" which were subject to limited review by us.

The Annual Financial results dealt with by this report have been prepared for the express purpose of filing with stock exchanges on which company shares are listed. These results are based on should be read with the audited financial statements of the company for the year ended March 31, 2024.

Our Opinion is not modified in respect of the above matter.

For A.M REDDY & D.R REDDY

Chartered Accountants



D. Rama Krishna Reddy

Partner

Membership No. 209211

UDIN: 24209211BKHHRV9902

Place: Hyderabad

Date: May 30, 2024